Ann Lab Med.  2015 Sep;35(5):506-509. 10.3343/alm.2015.35.5.506.

Therapeutic Plasma Exchange Using the Spectra Optia Cell Separator Compared With the COBE Spectra

• Kim DK
• Kim S
• Jeong SH
• Kim HO
• Kim HJ

• KMID: 2369766
• DOI: http://doi.org/10.3343/alm.2015.35.5.506

Abstract

BACKGROUND
The Spectra Optia (SPO) is a novel continuous-flow centrifugal apheresis system based on the COBE Spectra (CSP) platform. There have been few attempts to validate the advantages of the SPO. We performed a retrospective study comparing the two cell separators for therapeutic plasma exchange (TPE) procedures in kidney transplant (KT) patients and seeing efficacy and safety.
METHODS
We analyzed 720 TPE procedures performed between August 2012 and July 2014. Procedures included desensitization TPE before KT and TPE for the management of acute and chronic antibody-mediated graft rejection. Demographic characteristics, operational TPE variables, and laboratory data were analyzed.
RESULTS
Demographic characteristics for the SPO (n=389) and CSP (n=331) groups did not differ significantly. The procedure time to exchange one plasma volume was 94.2+/-10.3 min in the SPO group and 100.4+/-11.2 min in the CSP group (P<0.001). The plasma removal efficiency (PRE) was 92.5+/-4.9% in the SPO group and 83.2+/-3.7% in the CSP group (P<0.001). There were no significant differences across the two apheresis systems for changes in hematologic parameters.
CONCLUSIONS
Compared with the CSP, the SPO was associated with an improved PRE and a shorter procedure time to exchange one plasma volume. Our results in KT patients show that the SPO is superior to the CSP in TPE procedures.

Keyword

Apheresis; Plasma exchange; Kidney transplantation; Efficacy

MeSH Terms

Blood Component Removal
Graft Rejection
Humans
Kidney
Kidney Transplantation
Plasma
Plasma Exchange*
Plasma Volume
Retrospective Studies

Reference

1. Takahashi K. Recent findings in ABO-incompatible kidney transplantation: classification and therapeutic strategy for acute antibody-mediated rejection due to ABO-blood-group-related antigens during the critical period preceding the establishment of accommodation. Clin Exp Nephrol. 2007; 11:128–141. PMID: 17593512.

2. Jeon BJ, Kim IG, Seong YK, Han BH. Analysis of the results of ABO-incompatible kidney transplantation: In comparison with ABO-compatible kidney transplantation. Korean J Urol. 2010; 51:863–869. PMID: 21221208.

3. Kenmochi T, Saigo K, Maruyama M, Akutsu N, Iwashita C, Otsuki K, et al. Results of kidney transplantation from ABO-incompatible living donors in a single institution. Transplant Proc. 2008; 40:2289–2291. PMID: 18790214.

4. Oettl T, Halter J, Bachmann A, Guerke L, Infanti L, Oertli D, et al. ABO blood group-incompatible living donor kidney transplantation: a prospective, single-centre analysis including serial protocol biopsies. Nephrol Dial Transplant. 2009; 24:298–303. PMID: 18728155.

5. Thielke J, Kaplan B, Benedetti E. The role of ABO-incompatible living donors in kidney transplantation: state of the art. Semin Nephrol. 2007; 27:408–413. PMID: 17616273.

6. Schwartz J, Winters JL, Padmanabhan A, Balogun RA, Delaney M, Linenberger ML, et al. Guidelines on the use of therapeutic apheresis in clinical practice-evidence-based approach from the Writing Committee of the American Society for Apheresis: the sixth special issue. J Clin Apher. 2013; 28:145–284. PMID: 23868759.

7. Tormey CA, Peddinghaus ME, Erickson M, King KE, Cushing MM, Bill J, et al. Improved plasma removal efficiency for therapeutic plasma exchange using a new apheresis platform. Transfusion. 2010; 50:471–477. PMID: 19804570.

8. Hequet O, Stocco V, Assari S, Drillat P, Le QH, Kassir A, et al. Comparison of plasma exchange performances between Spectra Optia and COBE Spectra apheresis systems in repeated procedures considering variability and using specific statistical models. Transfus Apher Sci. 2014; 51:47–53. PMID: 25130725.

9. Yoo S, Lee EY, Huh KH, Kim MS, Kim YS, Kim HO. Role of plasma exchange in ABO-incompatible kidney transplantation. Ann Lab Med. 2012; 32:283–288. PMID: 22779070.

10. Reverberi R, Reverberi L. Removal kinetics of therapeutic apheresis. Blood Transfus. 2007; 5:164–174. PMID: 19204770.

11. Shemin D, Briggs D, Greenan M. Complications of therapeutic plasma exchange: a prospective study of 1,727 procedures. J Clin Apher. 2007; 22:270–276. PMID: 17722046.

12. De Silvestro G, Marson P, Russo GE, Vicarioto M, Donadel C. National survey of apheresis activity in Italy (2000). Transfus Apher Sci. 2004; 30:61–71. PMID: 14746823.

13. Norda R, Stegmayr BG. Swedish Apheresis Group. Therapeutic apheresis in Sweden: update of epidemiology and adverse events. Transfus Apher Sci. 2003; 29:159–166. PMID: 12941356.

14. Nadler SB, Hidalgo JH, Bloch T. Prediction of blood volume in normal human adults. Surgery. 1962; 51:224–232. PMID: 21936146.